Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/6/2026

1. MU
2. APTX:CN
3. SPY
4. IQMX
5. EROC
6. MSFT
7. MSTR
8. SEER
9. TSLA
10. FRBT

Go back to Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis
(NASDAQ: DERM) Delayed: 7.05 -0.04 (0.56%)
Previous Close $7.09    52 Week High $36.34 
Open $7.07    52 Week Low $17.42 
Day High $7.21    P/E N/A 
Day Low $6.89    EPS $0.00 
Volume 20,842